Global Anti-nuclear Antibody (ANA) Testing Market -  Forecast To 2027

Global Anti-nuclear Antibody (ANA) Testing Market information, by type (immunofluorescence, enzymelinked, immunosorbent assay (ELISA) and others), by application (Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Polymyositis, Scleroderma, Sjögren's syndrome, and others), by End User (Hospitals and clinics, research laboratories, and others) - Forecast to 2027

ID: MRFR/LS/2319-HCR | February 2021 | Region: Global | 72 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Synopsis of Global Anti-nuclear Antibody (ANA) Testing Market:


Anti-nuclear Antibody (ANA) Test is used to detect antinuclear antibodies in blood. Immune system makes antibodies to fight with various infections. Antinuclear antibodies often attack on own tissues. ANA test helps to determine autoimmune diseases like rheumatoid arthritis and lupus. Increasing technological advancements, adoption of new techniques and increasing prevalence of various autoimmune diseases are driving the growth for global anti-nuclear antibody (ANA) testing market. Major brands are investing money in R&D to develop more advanced product for the market that is another key driver for the market.


The Global Anti-nuclear Antibody (ANA) testing market is growing at the CAGR of ~9.6% during the forecast period and expected to reach US$ 1300.6 million by 2023.


Key Players for Global Anti-nuclear Antibody (ANA) Testing Market:     


Some of the key players in this market are: Abcam plc. (US), Alere (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Erba Diagnostics (US), Indur Services, Inc. (US), MBL INTERNATIONAL (US), Merck KGaA (Germany), Trinity Biotech (Republic of Ireland)


Intended Audience



  • Anti-nuclear Antibody (ANA) Test products manufacturers

  • Anti-nuclear Antibody (ANA) Test products and services providers

  • Medical Research laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Market Segments:      


Global Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others. On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others. On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.


FIGURE 1                   GLOBAL ANTI-NUCLEAR ANTIBODY (ANA) TESTING MARKET SHARE, BY APPLICATION (%)


ANTI-NUCLEAR ANTIBODY (ANA) TESTING MARKET SHARE, BY APPLICATION


Study objectives of Global Anti-nuclear Antibody (ANA) Testing Market:



  • To provide detailed analysis of the Global Anti-nuclear Antibody (ANA) Testing market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Anti-nuclear Antibody (ANA) Testing Market

  • To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Anti-nuclear Antibody (ANA) Testing market

  • To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide detail analysis of the market that segmented on the basis of type, by application, by end user, and its sub-segments.

  • To provide detail analysis of global Anti-nuclear Antibody (ANA) testing market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.

  • To provide detail country level analysis of the market with respect to the current market size and future prospective

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Anti-nuclear Antibody (ANA) Testing Market

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Anti-nuclear Antibody (ANA) Testing market


Regional Analysis of Global Anti-nuclear Antibody (ANA) Testing Market:               


Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.


Global Anti-nuclear Antibody (ANA) Testing Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology:
Research Methodology Anti-nuclear Antibody (ANA) Testing Market


 Sources: Directorate of Industries, Annual report, White paper, Company Presentation


The report for Global Anti-nuclear Antibody (ANA) Testing Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.



Frequently Asked Questions (FAQ) :


Anti-Nuclear Antibody Testing Market is projected to grow at a 9.6% CAGR between 2017-2023.

Anti-Nuclear Antibody Testing Market predicted to touch USD 1300.6 million by 2023.

North America is expected to dominate the Anti-Nuclear Antibody Testing Market.

Different end user industries of Anti-Nuclear Antibody Testing Market include research laboratories, hospital and clinics, and others.

Different strategies used by market players to create a dominance in the Anti-Nuclear Antibody Testing Market include mergers, acquisitions, collaborations, and product launches.

1. Report Prologue

2. Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

2.3 Market Structure

2.4. Market Segmentation

3. Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Mega Trends

4.5 Macroeconomic Indicators

5. Market Factor Analysis

5.1 Value Chain Analysis

5.2 Porters Five Forces

5.3 Demand & Supply: Gap Analysis

5.4 Pricing Analysis

5.5 Investment Opportunity Analysis

5.6 Merger and Acquisition Landscape

5.7 Upcoming trends

5.7.1 Market trends

5.7.2 Technological trends

5.7.3 Insurance & Regulations

5.7.4 Others

6. Global Anti-nuclear Antibody (ANA) Testing Market by Type

6.1 Immunofluorescence

6.1.1 Primary (direct)

6.1.2 Secondary (indirect)

6.2 Enzyme-linked immunosorbent assay (ELISA)

6.2.1 Direct ELISA

6.2.2 Indirect ELISA

6.2.3 Sandwich ELISA

6.2.4 Competition/Inhibition ELISA

6.3 Others

7. Global Anti-nuclear Antibody (ANA) Testing Market by Application

7.1 Rheumatoid arthritis

7.1.1 Seropositive

7.1.2 Seronegative

7.2 Lupus

7.2.1 Discoid lupus erythematosus,

7.2.2 Subacute cutaneous lupus erythematosus

7.2.3 Neonatal lupus

7.2.4 Systemic lupus erythematosus (SLE)

7.3 Polymyositis

7.4 Scleroderma

7.4.1 Localized scleroderma

7.4.2 Systemic scleroderma

7.5 Sjögren's syndrome

7.5.1 Primary

7.5.2 Secondary

7.6 Others

8. Global Anti-nuclear Antibody (ANA) Testing Market by End User

8.1 Hospitals and clinics

8.2 Research laboratories

8.3 Others

9. Global Anti-nuclear Antibody (ANA) Testing Market by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 The US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.3 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia

9.4.1 China

9.4.2 India

9.4.3 Japan

9.4.4 South Korea

9.4.5 Rest of Asia

9.5 Pacific

9.6 Middle East and Africa

9.6.1 UAE

9.6.2 Saudi Arabia

9.6.3 Egypt

9.6.4 Rest of Middle East and Africa

10. Competitive landscape

11. Company profile

12 Conclusion

12.1 Key findings

10.1.1 From CEO’s viewpoint

10.1.2 Unmet needs of the market

12.2 Key companies to watch

12.3 Prediction of Anti-nuclear Antibody (ANA) Testing Industry

13 Appendix